• Virionyx Corp. Ltd., of Auckland, New Zealand, said it changed its name to Innate Therapeutics Ltd. to reflect a repositioning of the company to focus development activities on drug candidate MIS416, a microparticle immune response modifier, in cancer, infectious and autoimmune diseases. The company plans to start a Phase I study this quarter and, if positive, will pursue Phase II trials in cancer in 2010. The firm also recently raised NZ$3 million (US$1.7 million) from existing New Zealand and U.S. shareholders to support the Phase I trial.